IRVINE, CA — (Marketwired) — 06/20/13 — TRIMEDYNE, INC. (OTCQB: TMED) today reported its financial results for the quarter and six month period ended March 31, 2013.Revenues for the current quarter were $1,570,000, an increase of 2.9% from revenues of $1,526,000 for the prior year-s quarter. The $44,000 increase in revenues was primarily due to higher revenues from sales of Needles and Fibers, compared to the prior year period. The Company had a net profit of $161,000 or $0.01 per share for
LAKE FOREST, CA — (Marketwire) — 02/20/13 — TRIMEDYNE, INC. (OTCBB: TMED) today reported its financial results for the first quarter of its fiscal year.Revenues for the quarter ended December 31, 2012, were $1,475,000, a 6% increase from revenues of $1,390,000 for the same quarter of the prior year. The Company had a net loss of $144,000 or $0.01 per share for the current quarter, compared to a loss of $285,000 or $0.02 per share for the same quarter of the prior year.At the end of the quart
LAKE FOREST, CA — (Marketwire) — 12/27/12 — TRIMEDYNE, INC. ("Trimedyne") (OTCBB: TMED) today announced Professor Anthony J. Costello, M.D., Head of the Department of Urology of the Royal Melbourne Hospital of the University of Melbourne (Australia), will serve as Lead Investigator in Asia and Southeast Asia, subject to their receiving funding, of the three (3), 300 patient, randomized, controlled clinical trials of Urodyne, Inc. ("Urodyne") in the treatment of Benign Pro
LAKE FOREST, CA — (Marketwire) — 12/21/12 — TRIMEDYNE, INC. ("Trimedyne") (OTCBB: TMED), today announced Graham M. Watson, M.D., has agreed to serve as Lead Investigator in Europe and the Middle East, subject to receiving funding, of the three (3), 300 patient, randomized clinical trials of Urodyne, Inc. ("Urodyne") to treat Benign Prostatic Hyperplasia or BPH, commonly referred to as an "Enlarged Prostate," urinary incontinence and fecal incontinence in Endosco
LAKE FOREST, CA — (Marketwire) — 12/20/12 — TRIMEDYNE, INC. ("Trimedyne") (OTCBB: TMED) today announced that Robert S. Cowles, III, M.D. has agreed to serve as Co-Chairman with Dr. Marvin P. Loeb of the Boards of Directors and as Medical Director of Urodyne, Inc. ("Urodyne") and Hyperdyne, Inc. ("Hyperdyne"), two subsidiaries Trimedyne plans to organize. (See Trimedyne-s Press Release of November 28, 2012).Dr. Cowles will be the Chief Investigator of, and subjec
LAKE FOREST, CA — (Marketwire) — 12/19/12 — TRIMEDYNE, INC. (OTCBB: TMED), today announced that Robert S. Cowles, III, M.D. has agreed to serve as Medical Director of Trimedyne. He will review Trimedyne-s new technologies and advise Trimedyne on the design of the clinical trials to be conducted, subject to receipt of funding, by the seven (7) subsidiaries Trimedyne plans to organize (See Trimedyne-s Press Release dated November 28, 2012).Dr. Cowles is an accomplished surgeon and a highly res
LAKE FOREST, CA — (Marketwire) — 11/28/12 — TRIMEDYNE, INC. (OTCBB: TMED) today announced it has patented and filed patent applications covering several new laser devices ("Devices") designed to treat medical conditions that affect millions of people in the United States and many more millions of people throughout the world.To establish the safety and efficacy of a new medical device in the treatment of a medical condition requires a large, expensive, randomized, controlled clinica
